Tipranavir monotherapy in treatment-experienced HIV patients with multiple reverse transcriptase mutations

Phase 3, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Papa Giovanni XXIII Hospital. Primary endpoints: Proportion of subjects with plasma HIV-RNA below 50 copies/mL at the end of follow-up and Composite virologic and immunologic response. Started Mar 2007; status: completed.